Investor Presentaiton

sanofi U.S. Advisory committee votes 21-0 in favor of nirsevimab FDA Unanimously voted in favor for 1st season Favorable benefit/risk profile for prevention of RSV LRTD in newborns & infants born during or entering 1st season Voted 19-2 in favor for 2nd season Favorable benefit/risk profile for prevention of RSV LRTD in children up to 24 months of age who remain vulnerable ACIP meeting anticipated before the RSV season 23 Vaccines Investor Event

View entire presentation